- Home
- IOBT vs BEAT Comparison
IOBT vs BEAT Comparison
Compare IOBT & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- BEAT
- Stock Information
- Founded
- IOBT 2014
- BEAT 2015
- Country
- IOBT Denmark
- BEAT United States
- Employees
- IOBT N/A
- BEAT N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- IOBT Health Care
- BEAT Technology
- Exchange
- IOBT Nasdaq
- BEAT Nasdaq
- Market Cap
- IOBT 59.3M
- BEAT 65.1M
- IPO Year
- IOBT 2021
- BEAT 2021
- Fundamental
- Price
- IOBT $1.10
- BEAT $2.08
- Analyst Decision
- IOBT Strong Buy
- BEAT Buy
- Analyst Count
- IOBT 3
- BEAT 1
- Target Price
- IOBT $9.33
- BEAT $8.00
- AVG Volume (30 Days)
- IOBT 120.7K
- BEAT 132.5K
- Earning Date
- IOBT 03-04-2025
- BEAT 03-19-2025
- Dividend Yield
- IOBT N/A
- BEAT N/A
- EPS Growth
- IOBT N/A
- BEAT N/A
- EPS
- IOBT N/A
- BEAT N/A
- Revenue
- IOBT N/A
- BEAT N/A
- Revenue This Year
- IOBT N/A
- BEAT N/A
- Revenue Next Year
- IOBT N/A
- BEAT N/A
- P/E Ratio
- IOBT N/A
- BEAT N/A
- Revenue Growth
- IOBT N/A
- BEAT N/A
- 52 Week Low
- IOBT $0.66
- BEAT $1.35
- 52 Week High
- IOBT $1.85
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- IOBT 68.67
- BEAT 39.34
- Support Level
- IOBT $0.91
- BEAT $2.05
- Resistance Level
- IOBT $1.14
- BEAT $2.37
- Average True Range (ATR)
- IOBT 0.06
- BEAT 0.18
- MACD
- IOBT 0.02
- BEAT -0.02
- Stochastic Oscillator
- IOBT 87.13
- BEAT 21.24
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.